<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363814</url>
  </required_header>
  <id_info>
    <org_study_id>MV130-SLG-35</org_study_id>
    <nct_id>NCT04363814</nct_id>
  </id_info>
  <brief_title>Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection</brief_title>
  <official_title>A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioClever 2005 S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm if BACTEK-R (MV130) provides clinical benefit in
      subject with mild pneumonia (CURB-65≤2) by COVID-19 admitted to the Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized pilot study to evaluate the efficacy and safety
      of BACTEK-R (MV130) in subject with mild pneumonia due to COVID-19 infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical recovery</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of subjects presenting a improvement in their clinical condition from day 1 to 14 that lead their hospital discharged. Based on the measure of the secondary outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of subjects presenting a worsening in their clinical condition from day 1 to 14 that leads to their admission to the intensive care unit or their death. Based on the measure of the secondary outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>Symptom (fever, cough, dyspnea, myalgia, diarrhea and so on) will be daily record and classified as mild, moderate, severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptoms remission</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time of reduction or disappearance of the symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Use</measure>
    <time_frame>2 weeks</time_frame>
    <description>Record of all the medication administered to the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time from the subject's admission to the coronavirus unit until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood routine test</measure>
    <time_frame>Days 1 and 7</time_frame>
    <description>Blood routine test will be carried out days 1 and 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>Heart rate will be followed everyday during time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>Blood pressure will be followed everyday during time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac auscultation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Cardiac auscultation will be recorded everyday during time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Blood oxygen saturation will be followed everyday during time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Adverse events during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Bactek-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject included in the experimental group will receive Bactek- R.The dose consists on 3 spray puff every 6 hours for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject included in the control group will receive standard therapy for COVID-19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bactek-R</intervention_name>
    <description>BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10^9 bacteria / mL)</description>
    <arm_group_label>Bactek-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Subjects who voluntarily sign informed consent forms

          2. - Both genders.

          3. - Subjects aged between 18 and 70 years.

          4. -Subjects capable of complying with the treatment

          5. - Subjects admitted to hospital with non-severe pneumonia (CURB-65≤2) by COVID-19

          6. - Confirmatory test for COVID-19 infection

        Exclusion Criteria:

          1. - Subjects who has not signed informed consent forms

          2. - Subjects included in another clinical trial.

          3. - Subjects under treatment with immunosuppressants.

          4. - Subjects in treatment with another type of immunotherapy.

          5. - Subjects who are or have been undergoing treatment with metformin.

          6. - Subjects who are or have been treated with statins.

          7. - Subjects who are or have been under treatment with sertraline.

          8. - Pregnant women.

          9. - Subjects who cannot offer cooperation and / or have serious psychiatric disorders.

         10. -Subjects who are allergic to any of the components of BACTEK-R (MV130).

         11. - Subjects with pathologies described in the Charlson index
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martín Medrano, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Batlle, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Raymundo Hernández</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Natalia García</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>M. Polanco</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Ángeles</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo Ángeles, MD</last_name>
    <phone>809 399 3520</phone>
    <email>gangeles@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <phone>+34916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Metropolitano Santiago</name>
      <address>
        <city>Santiago De Los Caballeros</city>
        <zip>51000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Batlle, MD</last_name>
      <phone>+1 829-947-2222</phone>
    </contact>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <reference>
    <citation>Cirauqui C, Benito-Villalvilla C, Sánchez-Ramón S, Sirvent S, Diez-Rivero CM, Conejero L, Brandi P, Hernández-Cillero L, Ochoa JL, Pérez-Villamil B, Sancho D, Subiza JL, Palomares O. Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways. Eur J Immunol. 2018 Jan;48(1):180-193. doi: 10.1002/eji.201747024. Epub 2017 Sep 14.</citation>
    <PMID>28799230</PMID>
  </reference>
  <reference>
    <citation>Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018 Jun;18(3):198-209. doi: 10.1097/ACI.0000000000000433.</citation>
    <PMID>29561355</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Ramón S, Pérez de Diego R, Dieli-Crimi R, Subiza JL. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects. Curr Drug Targets. 2014;15(12):1132-43. Review.</citation>
    <PMID>25330031</PMID>
  </reference>
  <reference>
    <citation>Tejera-Alhambra M, Palomares O, Perez de Diego R, Diaz-Lezcano I, Sanchez-Ramon S. New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice. Curr Pharm Des. 2016;22(41):6283-6293. doi: 10.2174/1381612822666160829143129. Review.</citation>
    <PMID>27573928</PMID>
  </reference>
  <reference>
    <citation>Alecsandru D, Valor L, Sánchez-Ramón S, Gil J, Carbone J, Navarro J, Rodríguez J, Rodríguez-Sainz C, Fernández-Cruz E. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011 Apr;164(1):100-7. doi: 10.1111/j.1365-2249.2011.04320.x.</citation>
    <PMID>21391984</PMID>
  </reference>
  <reference>
    <citation>Sánchez Ramón S, Manzanares M, Candelas G. MUCOSAL anti-infections vaccines: Beyond conventional vaccines. Reumatol Clin. 2020 Jan - Feb;16(1):49-55. doi: 10.1016/j.reuma.2018.10.012. Epub 2018 Dec 7. Review. English, Spanish.</citation>
    <PMID>30527360</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018 Dec 17;9:2936. doi: 10.3389/fimmu.2018.02936. eCollection 2018. Review.</citation>
    <PMID>30619296</PMID>
  </reference>
  <reference>
    <citation>Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004974. Review.</citation>
    <PMID>17054227</PMID>
  </reference>
  <reference>
    <citation>Lusuardi M. Challenging mucosal immunity with bacterial extracts to prevent respiratory infections: an old therapy revisited. Monaldi Arch Chest Dis. 2004 Jan-Mar;61(1):4-5.</citation>
    <PMID>15366329</PMID>
  </reference>
  <reference>
    <citation>García González LA, Arrutia Díez F. Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis. Hum Vaccin Immunother. 2019;15(9):2150-2153. doi: 10.1080/21645515.2019.1581537. Epub 2019 Apr 17.</citation>
    <PMID>30779677</PMID>
  </reference>
  <reference>
    <citation>Molero-Abraham M, Sanchez-Trincado JL, Gomez-Perosanz M, Torres-Gomez A, Subiza JL, Lafuente EM, Reche PA. Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation. Front Immunol. 2019 Jun 28;10:1434. doi: 10.3389/fimmu.2019.01434. eCollection 2019.</citation>
    <PMID>31316504</PMID>
  </reference>
  <reference>
    <citation>Randomised double-blind placebo-controlled, parallel, multi-centre clinical trial of sublingual bacterial vaccine in children with recurrent bronchospasm (wheezing attacks) for the evaluation of efficacy, security and clinical impact.</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

